Objective: To analyze the therapeutic significance of arsenite and thalidomide in patients with myelodysplastic syndrome. Methods: From August 2021 to August 2022, 80 patients with myelodysplastic syndrome were selected and randomly divided into two groups. In the control group, the drug used was thalidomide tablets, whereas in the observation group, the drug used was arsenite and thalidomide. The treatment effect was observed and evaluated. Results: Before treatment, there was no statistical significance in the blood and serological indices between the two groups. After treatment, the observation group showed better blood and serological indices than the control group (P < 0.05). The clinical efficacy of the observation group was 77.5%, while that of the control group was 50.0%. The observation group had significantly better treatment effect (P < 0.05). The incidence of adverse effects in the observation group and the control group was 5.0% and 20.0%, respectively. The observation group had significantly fewer adverse effects (P < 0.05). Conclusion: In the treatment of patients with myelodysplastic syndrome, the use of arsenite on the basis of thalidomide can effectively improve the treatment effect and optimize the levels of various blood and serological indices, with fewer adverse effects and a relatively high safety profile.
Wang G, Ma H, Zhao J, 2019, Clinical Value of Arsenite Combined with Thalidomide in the Treatment of 85 Patients with Myelodysplastic Syndrome. Electronic Journal of Cardiovascular Diseases of Integrated Traditional Chinese and Western Medicine, 7(26): 187–188.
Lu X, Wu X, Wu W, et al., 2019, Clinical Study on 47 Cases of Middle-High-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia with Decitabine Combined with Arsenite Induction Therapy. Chinese Journal of Practical Internal Medicine, 39(5): 452–455.
Lai B, Kang P, Chang Y, et al., 2019, Observation on the Effect of Arsenite Combined with Thalidomide in the Treatment of Patients with Myelodysplastic Syndrome. Modern Digestive and Interventional Diagnosis and Treatment, 2019(A01): 0058 –0059.
Mi R, Chen L, Chen L, et al., 2019, Effect and Safety Observation of Low-Dose Subcutaneous Injection of Decitabine Combined with Arsenic in the Treatment of Intermediate and High-Risk Myelodysplastic Syndromes. Leukemia and Lymphoma, 28(7): 396–400.
Wang Z, Xu M, Chen Y, et al., 2019, Four Cases of Acute Promyelocytic Leukemia Treatment-Related Myeloid Tumors and Literature Review. Chinese Journal of Hematology, 40(12): 1008–1014.
Huang X, 2020, Efficacy Analysis of Arsenite Injection Combined with Decitabine-Based Regimen in the Treatment of High-Risk MDS, thesis, Guangzhou University of Traditional Chinese Medicine.
Bai Y, Wang D, Wang Z, et al., 2020, Effect of TET2 Gene Mutation on the Efficacy of Children with Myelodysplastic Syndrome. Leukemia and Lymphoma, 29(7): 415–418.
Guo H, 2020, Treatment Perception of Patients with Multiple Skin Infections. Marriage and Childhood and Health, 2020(7): 26–27.
Li L, 2020, Analysis of Early Death Causes of Acute Promyelocytic Leukemia, thesis, Shandong University.
Zhang W, 2021, Retrospective Analysis of TADA Regimen and Decitabine in the Treatment of Myelodysplastic Syndrome, thesis, Yanbian University.
Dong W, 2022, Efficacy and Safety Analysis of Arsenite Combined with Thalidomide in the Treatment of Myelodysplastic Syndrome. Practical Chinese and Western Medicine, 22(2): 18–20 + 75.
Hu G, Dong K, Lu J, et al., 2021, Effects of Artesunate Combined with Arsenite on the Proliferation and Apoptosis of Multiple Myeloma Cells Via PI3K/AKT Signaling Pathway. Chinese Journal of Experimental Hematology, 29(6): 1819–1824.
Zhang S, Gao Y, Su Y, 2021, The Effect of Arsenous Acid on Multiple Myeloma and P38 Pathway. Modern Oncology, 29(1): 169–172.
Hu M, Zhang C, 2021, Retrospective Analysis of Arsenite System Therapy in the Treatment of Acute Promyelocytic Leukemia. China Science and Technology of Traditional Chinese Medicine, 28(4): 577–579.
Liu F, Qin X, Xiao D, 2020, Clinical Effect of All-Trans Retinoic Acid Combined with Arsenite in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia. Medical Information, 33(12): 67–69.